zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2009-6-4-5zdor-879Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEАЦЕТИЛЯТОРНЫЙ СТАТУС: СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУ (обзор литературы)THE ACETYLATED STATUS: PRESENT-DAY POINT OF VIEW ON THE SUBJECT (references review)СатыроваТ. В.SatyrovaT. V.noemail@neicon.ruГомельский государственный медицинский университетGomel State Medical University200928122009043136Copyright © Сатырова Т.В., 20092009Сатырова Т.В.Satyrova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/879

Изучение ацетиляторного полиморфизма не утрачивает своей актуальности не только потому, что многие лекарственные средства и канцерогенные вещества метаболизируются путем реакций ацетилирования, но также и потому, что были достигнуты успехи в понимании молекулярных основ ацетилирования. Именно эти генетически обусловленные вариации метаболизма лекарственных средств являются одной из причин индивидуальных особенностей эффекта фармакотерапии. У человека обнаружены два гена, отвечающих за деятельность фермента N-ацетилтрансферазы - NAT1 и NAT2. Исследования показали, что некоторые аллели этих генов влияют на индивидуальную восприимчивость к отдельным заболеваниям.

The study of acetylated polymorphism does not lose its actuality not only because plenty of remedies and carcinogenic substances metabolize by means of acetylization reactions, but also because much success has been achieved in the understanding of molecular bases of acetylation. Just these genetically due variations of remedy metabolism are one of the causes of individual peculiarities of pharmacotherapeutic effects. A man has two discovered genes, responsible for the activities of N-acetyltransferase enzyme - NAT1 и NAT2. The research has shown, that some alleles of these genes influence individual sensitivity to single illnesses.

N-ацетилтрансферазафенотипгенотипполиморфизм ацетилированиябыстрый ацетилятормедленный ацетиляторбиотрансформацияN-acetyltransferasephenotypegenotypepolymorphism of acetylationquick acetylatorslow acetylatorbiotransformationReferencesСереденин, С. Б. Лекции по фармакогенетике / С. Б. Середенин. - М.: Медицинское информационное агенство, 2004. - 303 с.Середенин, С. Б. Лекции по фармакогенетике / С. Б. Середенин. - М.: Медицинское информационное агенство, 2004. - 303 с.Meyer, U. A. Polymorphism of human acetyltransferases / U. A. Meyer // Environmental Health Perspectives. - 1994. - Vol. 102, № 6. - P. 213-216.Meyer, U. A. Polymorphism of human acetyltransferases / U. A. Meyer // Environmental Health Perspectives. - 1994. - Vol. 102, № 6. - P. 213-216.Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms / W. H. David [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9, № 1. - P. 29-42.Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms / W. H. David [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9, № 1. - P. 29-42.Molecular mechanism of slow acetylation of drugs and carcinogens in humans / M. Blum [et al.] // Proc. Natl. Acad. Sci. - 1991. - Vol. 88. - P. 5237-5241.Molecular mechanism of slow acetylation of drugs and carcinogens in humans / M. Blum [et al.] // Proc. Natl. Acad. Sci. - 1991. - Vol. 88. - P. 5237-5241.Correlation between acetylation phenotype and genotype in Chinese women / B. Zhao [et al.] // Eur. J. Clin. Pharmacol. - 2000. - Vol. 56. - P. 689-692.Correlation between acetylation phenotype and genotype in Chinese women / B. Zhao [et al.] // Eur. J. Clin. Pharmacol. - 2000. - Vol. 56. - P. 689-692.Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population / M. Gross [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 1999. - Vol. 8. - P. 683-692.Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population / M. Gross [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 1999. - Vol. 8. - P. 683-692.Ellard, G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis / G. A. Ellard // Clin. Pharmacol. Ther. - 1976. - Vol. 19. - P. 610-625.Ellard, G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis / G. A. Ellard // Clin. Pharmacol. Ther. - 1976. - Vol. 19. - P. 610-625.Hildebrand, M. Determination of acetylator phenotype in Caucasians with caffeine / M. Hildebrand, W. Seifert // Eur. J. Clin. Pharmacol. - 1989. - Vol. 37. - P. 525-526.Hildebrand, M. Determination of acetylator phenotype in Caucasians with caffeine / M. Hildebrand, W. Seifert // Eur. J. Clin. Pharmacol. - 1989. - Vol. 37. - P. 525-526.N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk / C. Bouchardy [et al.] // Pharmacogenetics. - 1998. - Vol. 8. - P. 291-298.N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk / C. Bouchardy [et al.] // Pharmacogenetics. - 1998. - Vol. 8. - P. 291-298.N-acetyltransferase polymorhisms and colorectal cancer: A HuGe review / N. Brockton [et al.] // Am. J. Epidemiol. - 2000. - Vol. 151. - P. 846-861.N-acetyltransferase polymorhisms and colorectal cancer: A HuGe review / N. Brockton [et al.] // Am. J. Epidemiol. - 2000. - Vol. 151. - P. 846-861.Snider, D. E. Jr. Pyridoxine supplementation during isoniazid therapy / D. E. Jr. Snider // Tubercle. - 1980. - Vol. 61. - P. 191-196.Snider, D. E. Jr. Pyridoxine supplementation during isoniazid therapy / D. E. Jr. Snider // Tubercle. - 1980. - Vol. 61. - P. 191-196.Azad Khan, A. K. The disposition and metabolism of sulfasalazine (salicylazosulphapyridine) in man / A. K. Azad Khan, S. C. Truelove, R. Aranson // Br. J. Clin. Pharmacol. - 1982. - Vol. 13. - P. 523-528.Azad Khan, A. K. The disposition and metabolism of sulfasalazine (salicylazosulphapyridine) in man / A. K. Azad Khan, S. C. Truelove, R. Aranson // Br. J. Clin. Pharmacol. - 1982. - Vol. 13. - P. 523-528.Das, K. M. Clinical pharmacokinetics of sulphasalazine / K. M. Das, R. Dubin // Clin. Pharmacikinet. - 1976. - Vol. 1, № 6. - P. 406-425.Das, K. M. Clinical pharmacokinetics of sulphasalazine / K. M. Das, R. Dubin // Clin. Pharmacikinet. - 1976. - Vol. 1, № 6. - P. 406-425.Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis / G. D. Kitas [et al.] // Scand. J. Rheumatol. - 1992. - Vol. 21. - P. 220-225.Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis / G. D. Kitas [et al.] // Scand. J. Rheumatol. - 1992. - Vol. 21. - P. 220-225.Spielberg, S. P. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism / S. P. Spielberg // J. Pharmacokinet. Biopharm. - 1996. - Vol. 24. - P. 509-519.Spielberg, S. P. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism / S. P. Spielberg // J. Pharmacokinet. Biopharm. - 1996. - Vol. 24. - P. 509-519.Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms / D. W. Hein [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9. - P. 29-42.Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms / D. W. Hein [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9. - P. 29-42.Johns, L.E. N-acetyl transferase-2 and bladder cancer risk: A meta-analysis / L. E. Johns, R. S. Houlston // Environ. Mol. Mutagen. - 2000. - Vol. 36. - P. 221-227.Johns, L.E. N-acetyl transferase-2 and bladder cancer risk: A meta-analysis / L. E. Johns, R. S. Houlston // Environ. Mol. Mutagen. - 2000. - Vol. 36. - P. 221-227.N-acetyltransferase 2 and bladder cancer: An overview and consideration of the evidence for gene-environment interaction / J. Green [et al.] // Br. J. Cancer. - 2000. - Vol. 83. - P. 412-417.N-acetyltransferase 2 and bladder cancer: An overview and consideration of the evidence for gene-environment interaction / J. Green [et al.] // Br. J. Cancer. - 2000. - Vol. 83. - P. 412-417.Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England / M. R. Welfare [et al.] // Carcinogenesis. - 1997. - Vol. 18. - P. 1351-1354.Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England / M. R. Welfare [et al.] // Carcinogenesis. - 1997. - Vol. 18. - P. 1351-1354.N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women / A. C. Deitz [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9. - P. 905-910.N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women / A. C. Deitz [et al.] // Cancer Epidemiol. Biomarkers and Prev. - 2000. - Vol. 9. - P. 905-910.NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore / A. Seow [et al.] // Carcinogenesis. - 1999. - Vol. 20. - P. 1877-1881.NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore / A. Seow [et al.] // Carcinogenesis. - 1999. - Vol. 20. - P. 1877-1881.N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation / T. Oyama [et al.] // Anticancer Res. - 1997. - Vol. 17. - P. 577-581.N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation / T. Oyama [et al.] // Anticancer Res. - 1997. - Vol. 17. - P. 577-581.A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people / T. Katoh [et al.] // Carcinogenesis. - 1998. - Vol. 19. - P. 1803-1807.A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people / T. Katoh [et al.] // Carcinogenesis. - 1998. - Vol. 19. - P. 1803-1807.

The authors declare that there are no conflicts of interest present.